Financials data is unavailable for this security.
View more
Year on year Oncternal Therapeutics Inc had revenues fall -47.32% from 1.49m to 785.00k, though the company grew net income from a loss of 44.17m to a smaller loss of 39.48m.
Gross margin | -- |
---|---|
Net profit margin | -1,948.70% |
Operating margin | -2,040.52% |
Return on assets | -96.40% |
---|---|
Return on equity | -118.06% |
Return on investment | -116.52% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Oncternal Therapeutics Inc fell by 30.45m. Cash Flow from Financing totalled 1.07m or 136.05% of revenues. In addition the company used 32.16m for operations while cash from investing totalled 651.00k.
Cash flow per share | -5.74 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.32 |
---|---|
Tangible book value per share | 5.32 |
More ▼
Balance sheet in USDView more
Current ratio | 2.89 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼